## SEQUENCE LISTING

<110 > Glaxo Group Limited. Bonnefoy, Jean-Yves Ellis, Jonathan H

<120> Antibody.

<130> PG3433

<140>

<141>

<150> GB 9809839.5 <151> 1998-05-09

<160> 53

<170> PatentIn Ver. 2.1

<210> 1

<211> 415

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (3)..(413)

<400> 1

aa gct tta cag tta ctc agc aca cag gac ctc acd atg gat ttt ggg 47 Ala Leu Gln Leu Leu Ser Thr Gln Asp Leu Thr Met Asp Phe Gly 15 10 1

ctg att ttt ttt att gtt ctt tta aaa ggg gtc cag agt gaa gtg aag Leu Ile Phe Phe Ile Val Leu Leu Lys Gly Val Gln Ser Gly Val Lys 25

ctt	gag	gag	tct	gga	gga	ggc	ttg	gtg	caa	cct	gga	gga	tcc	atg	aaa	143
Leu	Glu	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	Ser	Met	Lys	
			35					40					45			
ctc	tcc	tgt	gta	gcc	tct	gga	ttt	act	ttc	agt	ggc	tac	tgg	atg	tct	191
Leu	Ser	Cys	Val	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Gly	Tyr	Trp	Met	Ser	
		50					55					60				
tgg	gtc	cgc	cag	tct	cca	gag	aag	ggg	ctt	gag	tgg	gtt	gct	gaa	att	239
Trp	Val	Arg	Gln	Ser	Pro	Glu	Lys	Gly	Leu	Glu	Trp	Val	Ala	Glu	Ile	
	65					70					75					
aga	ttg	aaa	tct	gat	aat	tat	gca	aca	cat	tat	gcg	gag	tct	gtg	aaa	287
Arg	Leu	Lys	Ser	Asp	Asn	Tyr	Ala	Thr	His	Tyr	Ala	Glu	Ser	Val	Lys	
80					85					90					95	
ggg	aag	ttc	acc	atc	tca	aga	gat	gat	tcc	aaa	agt	cgt	ctc	tac	ctg	335
Gly	Lys	Phe	Thr	Ile	Ser	Arg	Asp	Asp	Ser	Lys	Ser	Arg	Leu	Tyr	Leu	
				100					105					110		
caa	atg	aac	agc	tta	aga	gct	gaa	gac	agt	gga	gtt	tat	tac	tgt	aca	383
Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu		Ser	Gly	Val	Tyr		Cys	Thr	
			115					120					125			
-		ata	-							gt						415
Asp	Phe	Ile	Asp	Trp	Gly	Gln		Thr	Leu							
		130					135									
	0> 2															
	1> 4:															
	2> DI															
<213	3> Mi	ıs mı	uscu.	ıus												
بمدر	n~															
<220	0> 1> CI	n s														
		3)	(437	١												
-42	(	-, • •	(40)	,												

٠٠, ١٠,

									3							
<40	00> 2	?														
aa	gct	tta	cag	tta	ctc	agc	aca	cag	gac	ctc	acc	atg	agg	ttc	tct	47
	Ala	Leu	Gln	Leu	Leu	Ser	Thr	Gln	Asp	Leu	Thr	Met	Arg	Phe	Ser	
	1				5					10					15	
gtt	cag	ttt	. ctg	999	gtg	ctt	atg	ttc	tgg	ato	tct	gga	gto	agt	ggg	95
Val	Gln	Phe	Leu	Gly	Val	Leu	Met	Phe	Trp	Ile	Ser	Gly	v Val	Ser	Gly	
				20	)				25					30		
gat	att	gtg	ata	acc	cag	gat	gaa	ctc	tcc	aat	cct	gto	act	tct	gga	143
Asp	Ile	Val	Ile	Thr	Gln	Asp	Glu	Leu	Ser	Asn	Pro	Val	Thr	Ser	Gly	
			35					40					45			
gaa	tca	gtt	tcc	atc	tcc	tgc	agg	tct	agt	aag	agt	ctc	ctg	tat	aag	191
Glu	Ser	Val	Ser	Ile	Ser	Cys	Arg	Ser	Ser	Lys	Ser	Leu	Leu	Tyr	Lys	
		50	)				55					60				
gat	ggg	aag	aca	tac	ttg	aat	tgg	ttt	ctg	cag	aga	cca	gga	caa	tct	239
Asp	Gly	Lys	Thr	Tyr	Leu	Asn	Trp	Phe	Leu	Gln	Arg	Pro	Gly	Gln	Ser	
	65					70					75					
cct	cag	ctc	ctg	atg	tat	ttg	atg	tcc	acc	cgt	gca	tca	gga	gtc	tca	287
Pro	Gln	Leu	Leu	Met	Tyr	Leu	Met	Ser	Thr	Arg	Ala	Ser	Gly	Val	Ser	
80					85					90					95	
gac	cgg	ttt	agt	ggc	agt	ggg	tca	ggc	aca	gat	ttc	acc	ctg	gaa	atc	335
Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Glu	Ile	
				100					105					110		
agt	aga	gtg	aag	gct	gag	gat	gtg	ggt	gtg	tat	tac	tgt	caa	caa	ctt	383
Ser	Arg	Val	Lys	Ala	Glu	Asp	Val	Gly	Val	Tyr	Tyr	Cys	Gln	Gln	Leu	
			115					120					125			

Val Glu Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
130 135 140

gta gag tat cca ttc acg ttc ggc tcg ggg aca aag ttg gaa ata aaa

. Э. ф. — т. — т. WO 99/58679

4

```
437
cgt acg
Arg Thr
    145
<210> 3
<211> 16
<212> PRT
<213> Mus musculus
<400> 3
Arg Ser Ser Lys Ser Leu Leu Tyr Lys Asp Gly Lys Thr Tyr Leu Asn
  1
                  5
                                      10
                                                          15
<210> 4
<211> 48
<212> DNA
<213> Mus musculus
<220>
<221> CDS
<222> (1)..(48)
<400> 4
cgc tcg agt aag agt ctc ctg tat aag gat ggg aag aca tac ttg aat
Arg Ser Ser Lys Ser Leu Leu Tyr Lys Asp Gly Lys Thr Tyr Leu Asn
                                                          15
                  5
                                      10
<210> 5
<211> 7
<212> PRT
<213> Mus musculus
<400> 5
Leu Met Ser Thr Arg Ala Ser
  1
                  5
```

Some grant in

PCT/GB99/01434 WO 99/58679

5

מוד דור - די ייים, וממו מודי ה. מווו מווני ע יו יו יו יווי יוווי או יווי

21

27

<210> 6

<211> 21

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1)..(21)

<400> 6

ttg atg tcc acc cgg gca tca

Leu Met Ser Thr Arg Ala Ser

1

<210> 7

<211> 9

<212> PRT

<213> Mus musculus

<400> 7

Gln Gln Leu Val Glu Tyr Pro Phe Thr 5

5

<210> 8

<211> 27

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1)..(27)

<400> 8

caa cag ctg gta gag tat cca ttc acg

Gln Gln Leu Val Glu Tyr Pro Phe Thr

WO 99/58679 PCT/GB99/01434

6

<210> 9

<211> 5

<212> PRT

<213> Mus musculus

<400> 9

Gly Tyr Trp Met Ser

1

5

<210> 10

<211> 15

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1)..(15)

<400> 10

ggc tac tgg atg tcc

Gly Tyr Trp Met Ser

1

5

<210> 11

<211> 19

<212> PRT

<213> Mus musculus

<400> 11

Glu Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser

1

5

10

15

15

Val Lys Gly

n.s. an nun mun min une m that nun to "h" to that the time

57

PCT/GB99/01434 WO 99/58679

7

<210> 12

<211> 57

<212> DNA

<213> Mus musculus

<220>

<221> CDS

<222> (1)..(57)

<400> 12

gaa att aga ttg aaa tct gat aat tat gca aca cat tat gcg gag tct Glu Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser 15

10 5

gtg aag ggg

Val Lys Gly

<210> 13

<400> 13

000

<210> 14

<400> 14

000

<210> 15

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic sequence

<400> 15

Met Gly Trp Ser Cys Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly

1

5

10

Val His Ser

<210> 16

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
sequence

<400> 16

Met Ala Trp Val Trp Thr Leu Leu Phe Leu Met Ala Ala Ala Gln Ser 1 5 10 15

Ala Gln Ala

<210> 17

<211> 348

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Humanised
 anti-CD23 antibody light chain variable region

<220>

<221> CDS

<222> (1)..(348)

<400> 17

gat att gtg atg act cag tct cca ctc tcc ctg ccc gtc acc cct gga 48

Asp Il Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly

1 5 10 15

gag	ccg	gcc	tcc	atc	tcc	tgt	cgc	tcg	agt	aag	agt	ctc	ctg	tat	aag	96
Glu	Pro	Ala	Ser	Ile	Ser	Cys	Arg	Ser	Ser	Lys	Ser	Leu	Leu	Tyr	Lys	
			20					25					30			
gat	999	aag	aca	tac	ttg	aat	tgg	tac	ctg	cag	aag	cca	ggg	cag	tct	144
Asp	Gly	Lys	Thr	Tyr	Leu	Asn	Trp	Tyr	Leu	Gln	Lys	Pro	Gly	Gln	Ser	
		35					40					45				
cca	cag	ctc	ctg	atc	tat	ttg	atg	tcc	acc	cgg	gca	tca	ggg	gtc	cct	192
Pro	Gln	Leu	Leu	Ile	Tyr	Leu	Met	Ser	Thr	Arg	Ala	Ser	Gly	Val	Pro	
	50					55					60					
gac	agg	ttc	agt	ggc	agt	gga	tca	ggc	aca	gat	ttt	aca	ctg	aaa	atc	240
Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Lys	Ile	
65					70					75					80	
agc	aga	gtg	gag	gct	gag	gat	gtt	ggg	gtt	tat	tac	tgt	caa	cag	ctg	288
Ser	Arg	Val	Glu	Ala	Glu	Asp	Val	Gly	Val	Tyr	Tyr	Cys	Gln	Gln	Leu	
				85					90					95		
gta	gag	tat	cca	ttc	acg	ttc	ggc	caa	ggg	acc	aag	gtg	gag	atc	aaa	336
Val	Glu	Tyr	Pro	Phe	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	lle	Lys	
			100					105					110			
cgt	acg	gtg	gct													348
Arg	Thr	Val	Ala													
		115														
<210	)> 18	3														
<211	l> 13	335														
<212	2> DI	AI														
<213	3> Ar	tifi	cial	. Sec	luenc	e										

<220>

<223> Description of Artificial Sequence: Humanised anti-CD23 antibody heavy chain variable region.

									10							
<220	)>															
<221	l> CI	os														
<222	2> (3	1)	(1335	5)												
<400	> 18	3														
gag	gtg	cag	ctg	gtg	gag	tct	aaa	gga	ggc	ttg	gta	aag	ccc	ggg	<b>gg</b> g	48
Glu	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Lys	Pro	Gly	Gly	
1				5					10					15		
tcc	ctt	aga	ctc	tcc	tgt	gca	gct	agc	gga	ttc	act	ttc	agt	ggc	tac	96
Ser	Leu	Arg		Ser	Cys	Ala	Ala		Gly	Phe	Thr	Phe	Ser	Gly	Tyr	
			20					25					30			
							gct									144
Trp	Met		Trp	Val	Arg	Gin	Ala	Pro	Gly	Lys	Gly		Glu	Trp	Val	
		35					40					45				
		-+-	.~.	****		+	~~+	+	+-+	<b>~~</b>	242		+ - +	~~~	<b>a</b> na	102
							gat Asp									192
Ala	50	116	Arg	Leu	ъув	55	изр	NS!!	ıyı	VIa	60	urs	ıyı	AIG	GIU	
	50					43					ŮŮ.					
tct	ata	ааσ	aaa	aaa	ttc	acc	atc	tca	aσa	αat	gat	tca	aaa	tct	aga	240
							Ile									
65		•	_	-4 "	70					75			•		80	
ctg	tat	ctg	caa	atg	aac	agc	ctg	aaa	acc	gag	gac	aca	gec	gtg	tat	288
Leu	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Lys	Thr	Glu	Asp	Thr	Ala	Val	Tyr	
				85					90					95		
tac	tgt	aca	gat	ttc	ata	gac	tgg	ggc	cag	gga	aca	cta	gtc	acc	gtc	336
Tyr	Cys	Thr	Asp	Phe	Ile	Asp	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	
			100					105					110			
tcc	tca	gcc	tcc	acc	aag	ggc	cca	tcg	gtc	ttc	ccc	ctg	gca	ccc	tcc	384

Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser

125

120

tcc	aag	agc	acc	tct	ggg	ggc	aca	gcg	gcc	ctg	ggc	tgc	ctg	gtc	aag	432
Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	Ala	Leu	Gly	Cys	Leu	Val	Lys	
	130					135					140					
gac	tac	ttc	ccc	gaa	ccg	gtg	acg	gtg	tcg	tgg	aac	tca	ggc	gcc	ctg	480
Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	Gly	Ala	Leu	
145					150					155					160	
acc	agc	ggc	gtg	cac	acc	ttc	ccg	gct	gtc	cta	cag	tcc	tca	gga	ctc	528
														Gly		
				165					170					175		
tac	tee	ctc	agc	agc	ata	ata	acc	ata	ccc	tcc	agc	agc	tta	ggc	acc	57 <i>6</i>
					-									Gly		
- , -	<b>D</b> C2	Dog	180	501				185					190	1		
			100					100					170			
<b>~</b> ~~	200	+20	ata	tac	220	ata	22+	Cac	220	ccc	200	220	200	aag	ata	624
_																027
GIN	THE	_	H	Cys	ASII	vai		UIS	гåр	PIO	Sel	205	1111	Lys	vai	
		195					200					205				
														tgc		672
Asp	Lys	Lys	Val	Glu	Pro		Ser	Cys	Asp	Lys	Thr	His	Thr	Cys	Pro	
	210					215					220					
ccg	tgc	cca	gca	cct	gaa	ctc	gcg	ggg	gca	ccg	tca	gtc	ttc	ctc	ttc	720
Pro	Cys	Pro	Ala	Pro	Glu	Leu	Ala	Gly	Ala	Pro	Ser	Val	Phe	Leu	Phe	
225					230					235					240	
ccc	cca	aaa	ccc	aag	gac	acc	ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	768
Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	
				245					250					255		
aca	tgc	gtg	gtg	gta	gac	gtg	agc	cac	gaa	gac	cct	gag	gtc	aag	ttc	816
	_		_		-									Lys		
	<b>4</b> -		260		٠			265		•			270	-		

			-	•				_			gcc Ala					864
		275					280					285				
cgg	gag	gag	cag	tac	aac	agc	acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	912
Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	
	290					295					300					
gtc	ctg	cac	cag	gac	tgg	ctg	aat	ggc	aag	gag	tac	aag	tgc	aag	gtc	960
Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	
305					310					315					320	
tcc	aac	aaa	gcc	ctc	cca	gcc	ccc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	1008
Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	
				325					330					335		
aaa	ggg	cag	CCC	cga	gaa	cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	cgg	1056
Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Arg	
			340					345					350			
gat	gag	ctg	acc	aag	aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	1104
Asp	Glu		Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys		Val	Lys	Gly	
		355					360					365				
ttc	tat	ccc	agc	gac	atc	gcc	gtg	gag	tgg	gag	agc	aat	ggg	cag	ccg	1152
Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser	Asn	Gly	Gln	Pro	
	370					375					380					
gag	aac	aac	tac	aag	acc	acg	cct	ccc	gtg	ctg	gac	tcc	gac	ggc	tcc	1200
Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp	Ser	Asp	Gly	Ser	
385					390					395					400	
ttc	ttc	ctc	tac	agc	aag	ctc	acc	gtg	gac	aag	agc	agg	tgg	cag	cag	1248
Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser	Arg	Trp	Gln	Gln	
				405					410					415		

t i m, mi ii m rn rn itim ma mis.

mis si mei

ggg aac gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 420 425 430 tac acg cag aag agc ctc tcc ctg tct ccg ggt aaa tga 1335 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 <210> 19 <211> 57 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 19 gatgaagctt tacagttact cagcacacag gacctcacca tggattttgg gctgatt <210> 20 <211> 25 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 20 25 gatggactag tgtcccttgg cccca <210> 21 <211> 57 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo

. . .

<400> 21	
gatgaagett tacagttact cagcacacag gaceteacea tgaggttete tgtteag	57
<210> 22	
<211> 28	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Oligo	
<400> 22	
gatgcgtacg tytkatytcc avcttkgt	28
<210> 23	
<211> 30	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Oligo	
<400> 23	
gatcaagctt ctctacagtt actgagcaca	30
<210> 24	
<211> 63	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Oligo	
<400> 24	
aatcaagtat gtcttcccat ccttatacag gagactctta ctcgagcgac aggagatgga	60
ggc	63

<210> 25	
<211> 63	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Oligo	
<400> 25	
cgctcgagta agagtctcct gtataaggat gggaagacat acttgaattg gtacctgcag	
aag	63
<210> 26	
<211> 36	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Oligo	
<400> 26	
tgatgcccgg gtggacatca aatagatcag gagctg	36
<210> 27	
<211> 36	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Oligo	
44005 07	
<400> 27	36
ttgatgtcca cccgggcatc aggggtccct gacagg	50
<210> 28	
<211> 84	
<212> DNA	
<213> Artificial Sequence	

n 5 mai mi. m mi. mm mm. com ace man

<220> <223> Description of Artificial Sequence: Oligo <400> 28 agccacctga cgtttgatct ccaccttggt cccttggccg aacgtgaatg gatactctac 60 cagctgttga cagtaataaa cccc 84 <210> 29 <211> 60 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 29 acacgaaget teaccatgge ttgggtgtgg acettgetat teetgatgge ggeegeecaa 60 <210> 30 <211> 66 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 30 ctttaccaag cctcccccag actccaccag ctgcacctct gcttgggcac ttttgggcggc 60 66 cgccat <210> 31 <211> 60 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo

. . . . . .

<400> 31 ttggtaaagc ccggggggtc ccttagactc tcctgtgcag ctagcggatt cactttcagt 60 <210> 32 <211> 60 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 32 ccccttccct ggagcctggc ggacccagga catccagtag ccactgaaag tgaatccgct 60 <210> 33 <211> 60 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 33 gggaaggggc tcgagtgggt tgctgaaatt agattgaaat ctgataatta tgcaacacat 60 <210> 34 <211> 60 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo

<400> 34

atcatetett gagatggtga attteceett cacagactee geataatgtg ttgcataatt 60

המוני מה מחום מחום מחום בהו זו יותר חום יה זו יה לחוף יה לחוף

WO 99/58679 PCT/GB99/01434

18

<210> 35 <211> 66 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 35 atctcaagag atgattcaaa atctagactg tatctgcaaa tgaacagcct gaaaaccgag 60 66 gacaca <210> 36 <211> 69 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 36 ggtgactagt gttccctggc cccagtctat gaaatctgta cagtaataca cggctgtgtc 60 69 ctcggtttt <210> 37 <211> 48 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Oligo <400> 37 48 gctgctcctt ttaagctttg gggtcaaggc tcactagtca cagtctcc

<210> 38	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Oligo	
<400> 38	
tgacggtgcc cccgcgagtt cagg	24
<210> 39	
<211> 24	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Oligo	
4400 20	
<400> 39	24
cctgaactcg cgggggcacc gtca	
<210> 40	
<211> 33	
<212> DNA	
<213> Artificial Sequence	
<220>	
<223> Description of Artificial Sequence: Oligo	
<400> 40	33
aagetteegt egaatteatt taeeeggaga eag	3.
<210> 41	
<211> 37	

Find the Work or the of mills were in more more men men and me. more

37

WO 99/58679 PCT/GB99/01434

20

<220> <223> D scription of Artificial Sequence: Primer <400> 41 actagtcgac atgaagtttc cttctcaact tctgctc <210> 42 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic sequence <400> 42 Thr Lys Leu Glu Ile Lys Arg Thr <210> 43 <211> 8 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic sequence <400> 43 Thr Lys Val Glu Ile Lys Arg Thr

<210> 44

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic sequence

<400> 44

Thr Lys Leu Glu Ile Arg Arg Thr

5

1

<210> 45

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
sequence

<400> 45

Thr Lys Val Glu Ile Arg Arg Thr

1 5

<210> 46

<211> 415

<212> DNA

<213> Mus musculus

<400> 46

actagtgtcc cttggccca gtctatgaaa tctgtacagt aataaactcc actgtcttca 60 gctcttaagc tgttcatttg caggtagaga cgacttttgg aatcatctct tgagatggtg 120 aacttccctt tcacagactc cgcataatgt gttgcataat tatcagattt caatctaatt 180 tcagcaaccc actcaagccc cttctctgga gactggcgga cccaagacat ccagtagcca 240 ctgaaagtaa atccagaggc tacacaggag agtttcatgg atcctccagg ttgcaccaag 300 cctcctccag actcctcaag cttcacttca ctctggaccc cttttaaaag aacaataaaa 360 aaaatcagcc caaaatccat ggtgaggtcc tgtgtgctga gtaactgtaa agctt 415

. •

PCT/GB99/01434

22

WO 99/58679

<212> DNA

<213> Artificial Sequence

<210> 47 <211> 437 <212> DNA <213> Mus musculus <400> 47 cgtacgtttt atttccaact ttgtccccga gccgaacgtg aatggatact ctacaagttg 60 ttgacagtaa tacacaccca catcctcagc cttcactcta ctgatttcca gggtgaaatc 120 tgtgcctgac ccactgccac taaaccggtc tgagactcct gatgcacggg tggacatcaa 180 atacatcagg agctgaggag attgtcctgg tctctgcaga aaccaattca agtatqtctt 240 cccatcctta tacaggagac tcttactaga cctgcaggag atggaaactg attctccaga 300 agtgacagga ttggagagtt catcctgggt tatcacaata tccccactga ctccaqagat 360 ccagaacata agcacccca gaaactgaac agagaacctc atggtgaggt cctgtgtqct 420 gagtaactgt aaagctt 437 <210> 48 <211> 348 <212> DNA <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Humanised anti-CD23 antibody light chain variable region <400> 48 agccaccgta cgtttgatct ccaccttggt cccttggccg aacgtgaatg gatactctac 60 cagctgttga cagtaataaa ccccaacatc ctcagcctcc actctgctga ttttcagtgt 120 aaaatctgtg cctgatccac tgccactgaa cctgtcaggg acccctgatg cccgggtgga 180 catcaaatag atcaggagct gtggagactg ccctggcttc tgcaggtacc aattcaagta 240 tgtcttccca tccttataca ggagactctt actcgagcga caggagatgg aggccggctc 300 tccaggggtg acgggcaggg agagtggaga ctgagtcatc acaatatc 348 <210> 49 <211> 1335

<220>

<400> 49

<223> Description of Artificial Sequence: Humanised anti-CD23 antibody heavy chain variable region

tcatttaccc ggagacaggg agaggctctt ctgcgtgtag tggttgtgca gagcctcatg 60 catcacggag catgagaaga cgttcccctg ctgccacctg ctcttgtcca cggtgagctt 120 gctgtagagg aagaaggagc cgtcggagtc cagcacggga ggcgtggtct tgtagttgtt 180 ctccggctgc ccattgctct cccactccac ggcgatgtcg ctgggataga agcctttgac 240 caggcaggtc aggctgacct ggttcttggt cagctcatcc cgggatgggg gcagggtgta 300 cacctgtggt tetegggget geeetttgge tttggagatg gttttetega tgggggetgg 360 gagggetttg ttggagacet tgcacttgta etecttgeca tteagecagt cetggtgeag 420 gacggtgagg acgctgacca cacggtacgt gctgttgtac tgctcctccc gcggctttgt 480 cttggcatta tgcacctcca cgccgtccac gtaccagttg aacttgacct cagggtcttc 540 gtggctcacg tccaccacca cgcatgtgac ctcaggggtc cgggagatca tgagggtgtc 600 cttgggtttt ggggggaaga ggaagactga cggtgccccc gcgagttcag gtgctgggca 660 cggtgggcat gtgtgagttt tgtcacaaga tttgggctcc actttcttgt ccaccttggt 720 gttgctgggc ttgtgattca cgttgcagat gtaggtctgg gtgcccaagc tgctggaggg 780 cacggtcacc acgctgctga gggagtagag tcctgaggac tgtaggacag ccgggaaggt 840 gtgcacgccg ctggtcaggg cgcctgagtt ccacgacacc gtcaccggtt cggggaagta 900 gtccttgacc aggcagccca gggccgctgt gcccccagag gtgctcttgg aggagggtgc 960 cagggggaag accgatgggc ccttggtgga ggctgaggag acggtgacta gtgttccctg 1020 gcccagtct atgaaatctg tacagtaata cacggctgtg tcctcggttt tcaggctgtt 1080 catttgcaga tacagtctag attttgaatc atctcttgag atggtgaatt tccccttcac 1140 agactccgca taatgtgttg cataattatc agatttcaat ctaatttcag caacccactc 1200 gagccccttc cctggagcct ggcggaccca ggacatccag tagccactga aagtgaatcc 1260 gctagctgca caggagagtc taagggaccc cccgggcttt accaagcctc ccccagactc 1320 1335 caccagetge acete

<210> 50

<211> 137

<212> PRT

<213> Mus musculus

<400> 50

Ala Leu Gln Leu Leu Ser Thr Gln Asp Leu Thr Met Asp Phe Gly Leu

1 5 10 15

an a war and a train me, at the most about the war war.

24

Ile Phe Phe Ile Val Leu Leu Lys Gly Val Gln Ser Glu Val Lys Leu 20 25 30

Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Met Lys Leu 35 40 45

Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Gly Tyr Trp Met Ser Trp 50 55 60

Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val Ala Glu Ile Arg
65 70 75 80

Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu Ser Val Lys Gly
85 90 95

Lys Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Arg Leu Tyr Leu Gln
100 105 110

Met Asn Ser Leu Arg Ala Glu Asp Ser Gly Val Tyr Tyr Cys Thr Asp 115 120 125

Phe Ile Asp Trp Gly Gln Gly Thr Leu 130 135

<210> 51

<211> 145

<212> PRT

<213> Mus musculus

<400> 51

Ala Leu Gln Leu Leu Ser Thr Gln Asp Leu Thr Met Arg Phe Ser Val

Gln Phe Leu Gly Val Leu Met Phe Trp Ile Ser Gly Val Ser Gly Asp 20 25 30

Ile Val Ile Thr Gln Asp Glu Leu Ser Asn Pro Val Thr Ser Gly Glu
35 40 45

WO 99/58679

25 Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Lys Asp 60 50 Gly Lys Thr Tyr Leu Asn Trp Phe Leu Gln Arg Pro Gly Gln Ser Pro 75 80 70 65 Gln Leu Leu Met Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Ser Asp 90 95 85 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Glu Ile Ser 110 100 105 Arg Val Lys Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu Val 120 125 115 Glu Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Arg 135 130 Thr 145 <210> 52 <211> 116 <212> PRT <213> Artificial Sequence <223> Description of Artificial Sequence: Humanised anti-CD23 antibody light chain variable region <400> 52 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly 10 15 5 Glu Pro Ala Ser Ile Ser Cys Arg Ser Les Ser Leu Leu Tyr Lys 30 20 25

Asp Gly Lys Thr Tyr Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser

WO 99/58679 PCT/GB99/01434

26

Pro Gln Leu Leu Ile Tyr Leu Met Ser Thr Arg Ala Ser Gly Val Pro 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Gln Gln Leu 85 90 95

Val Glu Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110

Arg Thr Val Ala

<210> 53

<211> 444

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Humanised anti-CD23 antibody heavy chain variable region.

<400> 53

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Gly Tyr
20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Glu Ile Arg Leu Lys Ser Asp Asn Tyr Ala Thr His Tyr Ala Glu
50 55 60

Ser Val Lys Gly Lys Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Arg
65 70 75 80

## WO 99/58679

PCT/GB99/01434

Leu	Tyr	Leu	Gln	Met 85	Asn	Ser	Leu	Lys	Thr 90	Glu	Asp	Thr	Ala	Val 95	Туг
Tyr	Cys	Thr	Asp	Phe	Ile	Asp	Trp	Gly 105	Gln	Gly	Thr	Leu	Val	Thr	Val
Ser	Ser	Ala 115	Ser	Thr	Lys	Gly	Pro 120	Ser	Val	Phe	Pro	Leu 125	Ala	Pro	Ser
Ser	<b>L</b> ys 130	Ser	Thr	Ser	Gly	Gly 135	Thr	Ala	Ala	Leu	Gly 140	Cys	Leu	Val	Lys
Asp 145	Туг	Phe	Pro	Glu	Pro 150	Val	Thr	Val	Ser	Trp 155	Asn	Ser	Gly	Ala	Leu 160
Thr	Ser	Gly	Val	His 165	Thr	Phe	Pro	Ala	Val 170	Leu	Gln	Ser	Ser	Gly 175	Leu
Tyr	Ser	Leu	Ser 180	Ser	Val	Val	Thr	Val 185	Pro	Ser	Ser	Ser	Leu 190	Gly	Thr
Gln	Thr	<b>Tyr</b> 195	Ile	Cys	Asn	Val	Asn 200	His	Lys	Pro	Ser	<b>A</b> sn 205	Thr	Lys	Val
Asp	Lys 210	Lys	Val	Glu	Pro	Lys 215	Ser	Cys	Asp	Lys	Thr 220	His	Thr	Cys	Pro
<b>Pr</b> o <b>22</b> 5	Cys	Pro	Ala	Pro	Glu 230	Leu	Ala	Gly	Ala	Pro 235	Ser	Val	Phe	Leu	Phe
Pro	Pro	Lys	Pro	Lys 245	Asp	Thr	Leu	Met	Ile 250	Ser	Arg	Thr	Pro	Glu 255	Val
Thr	Cys	Val	<b>V</b> al	Val	Asp	Val	Ser	His 265	Glu	Asp	Pro	Glu	Val 270	Lys	Phe
Asn	Trp	Tyr 275	Val	Asp	Gly	Val	Glu 280	Val	His	Asn	Ala	Lys 285	Thr	Lys	Pro

with the settle of the control of th

28

Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 290 295 300

Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 305 310 315 320

Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 325 330 335

Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg

Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 355 360 365

Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 370 375 380

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 385

Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 415

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435
440

. • •) •